Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model

Human head and neck squamous cell carcinoma (HNSCC) is usually treated by surgical resection with adjuvant radio-chemotherapy. In this study, we examined whether the radiopharmaceutical188Re-liposome could suppress the growth of HNSCC followed by an investigation of molecular mechanisms. The orthotopic HNSCC tumor model was established by human hypopharyngeal FaDu carcinoma cells harboring multiple reporter genes. The drug targeting and therapeutic efficacy of188Reliposome were examined using in vivo imaging, bio-distribution, pharmacokinetics, and dosimetry. The results showed that188Re-liposome significantly accumulated in the tumor lesion compared to free188Re. The circulation time and tumor targeting of188Re-liposome were also longer than that of free188Re in tumor-bearing mice. The tumor growth was suppressed by188Re-liposome up to three weeks using a single dose treatment. Subsequently, microarray analysis followed by Ingenuity Pathway Analysis (IPA) showed that tumor suppressor let-7 microRNA could be an upstream regulator induced by188Re-liposome to regulate downstream genes. Additionally, inhibition of let-7i could reduce the effects of188Re-liposome on suppression of tumor growth, suggesting that let-7 family was involved in188Re-liposome mediated suppression of tumor growth in vivo. Our data suggest that188Re-liposome could be a novel strategy for targeting HNSCC partially via induction of let-7 microRNA.